Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Payables (2022 - 2025)

Historic Payables for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $1.4 million.

  • 60 Degrees Pharmaceuticals' Payables rose 10532.94% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 10532.94%. This contributed to the annual value of $1.0 million for FY2024, which is 9905.3% up from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Payables stood at $1.4 million for Q3 2025, which was up 10532.94% from $905813.0 recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' Payables peaked at $27.0 million during Q2 2023, and registered a low of $506206.0 during Q4 2023.
  • Moreover, its 4-year median value for Payables was $1.0 million (2024), whereas its average is $4.9 million.
  • In the last 5 years, 60 Degrees Pharmaceuticals' Payables plummeted by 9762.1% in 2024 and then skyrocketed by 11871.4% in 2025.
  • 60 Degrees Pharmaceuticals' Payables (Quarter) stood at $17.6 million in 2022, then crashed by 97.13% to $506206.0 in 2023, then soared by 99.05% to $1.0 million in 2024, then surged by 38.08% to $1.4 million in 2025.
  • Its Payables was $1.4 million in Q3 2025, compared to $905813.0 in Q2 2025 and $1.2 million in Q1 2025.